Bayer's Science Is Advancing Faster Than Its Revenue Line — and the Street Knows It
Published on 10/27/2026 at 22:31 | Editorial boerse-global.de
Two clinical announcements in the space of four days have given Bayer investors plenty to cheer about. What they have not given them is a single euro of confirmed additional revenue. That gap — between a promising dataset and a booked sale — sits at the heart of how the market is pricing the German group's pharmaceutical pipeline right now.
The medical news is genuinely strong. Bayer reported on Saturday that darolutamide, sold as Nubeqa, cut the risk of metastases or death by 58% versus placebo when added to androgen deprivation therapy and radiotherapy. The interim analysis from the Phase III DASL-HiCaP trial covered prostate cancer patients at high risk of recurrence. The four-year metastasis-free survival rate came in at 95%, against 88% for placebo.
Separately, China granted approval on the previous day for Asundexian, to be marketed there as Sunharbo, following an accelerated review. The drug reduces stroke risk after a non-cardioembolic ischaemic stroke or in high-risk TIA. Bayer describes it as the first factor XIa inhibitor cleared anywhere in the world.
What the analysts actually said
Goldman Sachs' James Quigley and JPMorgan's Richard Vosser put the additional sales potential from Nubeqa at up to EUR 1 billion. Vosser, reacting to the DASL-HiCaP data, kept his "Overweight" rating and his EUR 61 price target unchanged.
That distinction matters more than it might appear. The estimate is a projection tied to trial data — not a reported revenue increase, not company guidance, and not a ratings upgrade. Treating the top of that range as money in the bank skips a step that no analyst has taken.
Should investors sell immediately? Or is it worth buying Bayer?
The same caution applies to Asundexian. A regulatory green light is a completed decision; what the product eventually contributes to the top line remains an open question. Lumping the two announcements together, or bolting an assumed Asundexian contribution onto the Nubeqa figure, would blur the line between a clinical result and a commercial one.
A broader pipeline, a narrower read-across
Thursday brought further colour. Bayer presented subanalyses from the Phase III FIND-CKD trial, reporting consistent effects from finerenone on proteinuria and on the decline in kidney function versus placebo in chronic kidney disease patients without diabetes.
Taken together, the run of news — an approval, an interim Phase III readout, and supporting subanalyses — paints a picture of a pipeline delivering on several fronts. It does not, however, produce a single combined revenue number, and investors should resist manufacturing one.
There is also a matter of stage. Asundexian has a regulatory approval in hand. Darolutamide's headline rests on an interim analysis. Finerenone's comes from subanalyses. None of that diminishes the value of the data; it simply demands precision about what each item proves.
The market has already voted
Bayer shares rose on the back of both drug announcements, according to dpa-AFX. That means the good news has already triggered a market reaction — and with it, the risk that expectations outrun commercial confirmation. Strong science alone does not tell investors how much future business to capitalise into today's price.
The bear case here is not about the results themselves. It is about reach. A relative risk reduction in a trial is not a sales forecast, and a Chinese approval says nothing on its own about Asundexian's eventual earnings contribution. Equating the two would mix medical endpoints with financial metrics.
Bayer at a turning point? This analysis reveals what investors need to know now.
JPMorgan's response offers a useful yardstick. The bank was positive, yet left both rating and target untouched. That is neither a downgrade nor a fresh upgrade — just a confirmation that the data supported the existing thesis without adding to it.
November 3 is the next real test
The growth story holds together as long as the clinical momentum is underpinned by commercial delivery. It gains weight if Bayer can put numbers behind the opportunity. Should the revenue assumptions prove too ambitious, the valuation of that opportunity would need to come down — even with the trial data unchanged.
The next hard datapoint is the third-quarter 2026 report, scheduled for November 3, 2026 at 07:30 CET, with a media update set for 10:00 CET. Investors will be watching whether operating performance and the longer-term drug outlook form a coherent whole. The release will not, by itself, validate the analyst estimate — and it should not be read as immediate proof of the approval or the trial results just announced.
For now, the science is ahead. The revenue line has some catching up to do.
Ad
Bayer Stock: New Analysis - 27 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
